J. Haba

发表

Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial

I. Tusquets, L. Calvo, J. Rifá, 2009, Breast Cancer Research and Treatment.

Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

C. Jara, E. Ciruelos, J. Baena, 2015, Clinical and Translational Oncology.

Challenges in Prognosis, Systemic Therapy, and Survival in Patients with HER2-Negative Metastatic Breast Cancer candidates to systemic chemotherapy

S. Cosimo, C. Barrios, J. Pérez-García, 2017 .

A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study

J. Brunet, A. Guerrero-Zotano, A. Llombart-Cussac, 2020, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)

J. Albanell, A. Lluch, L. Calvo, 2017, Clinical and Translational Oncology.

Abstract OT3-02-04: Randomised phase II study evaluating, as first-line chemotherapy, single-agent oral vinorelbine administered with two different schedules in patients with hormone receptor positive, HER2-negative advanced breast cancer (TempoBreast-1 trial)

F. Cardoso, E. Starosławska, E. Petru, 2016 .

Abstract S1-7: Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer – First efficacy results from the LEA study.

S. Loibl, C. Liedtke, M. Martín, 2012 .

Abstract P6-08-10: Prospective study of the impact of the Prosigna™ assay on adjuvant clinical decision-making in women with estrogen receptor-positive, HER2-negative, node-negative breast cancer: A GEICAM study

J. Hornberger, F. Rojo, J. Albanell, 2015 .

Prognostic and predictive factors and genetic analysis of early breast cancer

J. Schneider, Miguel Martín, J. Cortés, 2009, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Abstract CT219: Neoadjuvant letrozole and palbociclib in stage II-IIIB HR[+]/HER2[-] breast cancer with Oncotype DX Recurrence Score®(RS) 18-25 or 26-100. Analysis of RS changes at surgery (DxCARTES trial)

J. Albanell, A. Urruticoechea, M. Margelí, 2019, Clinical Trials.

Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register

A. Ruíz, A. Lluch, E. Alba, 2010, Breast Cancer Research and Treatment.

Potential application of GSTT 1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients

E. Bandrés, J. García-Foncillas, E. Aranda, 2022 .

Luminal androgen receptor role and pathological complete response rate to neoadjuvant chemotherapy in triple negative breast cancer

J. M. Jerez, J. Albanell, A. Prat, 2016 .

Chemotherapy (CT) versus hormone therapy (HT) as neoadjuvant treatment in luminal breast cancer: A multicenter, randomized phase II study (GEICAM/2006-03).

J. Albanell, A. Lluch, E. Alba, 2010 .

Multifocality and multicentricity in breast cancer and survival outcomes

J. Albanell, A. Lluch, E. Carrasco, 2012 .

Abstract OT2-01-06: Phase III study of palbociclib (PD-0332991) in combination with endocrine therapy (exemestane or fulvestrant) versus chemotherapy (capecitabine) in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with resistance to aromatase inhibitors.“The P

M. Koehler, M. Margelí, C. H. Bartlett, 2017 .

Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study.

A. Tres, E. Alba, M. Martín, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Breast cancer, locally advanced and metastatic

L. Holmberg, O. Nanni, S. Barni, 2012 .

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial

F. Rojo, J. Albanell, A. Lluch, 2014, British Journal of Cancer.

Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study.

J. Albanell, A. Lluch, E. Alba, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

The quotient of number of nodes and tumour size (N/T) from primary breast cancer predicts the clinical course after diagnosis of distant relapse.

N. Ribelles, E. Aranda, R. Dueñas, 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients.

E. Bandrés, J. García-Foncillas, E. Aranda, 2006, Oncology reports.

Different Treatment Benefit for Luminal A and Luminal B Advanced Breast Cancinomas Receiving Aromatase Inhibitors.

M. Ruíz-Borrego, J. Palacios, F. Carabantes, 2009 .